Category: Expert Interview
-
Beyond animal models: The new FDA human-first drug development framework
Dr Greg Tietjen, CEO of Revalia Bio, discusses the FDA’s push for human-first data and how it’s reshaping the entire drug development pipeline.
-
Smarter Trials: Inside Vivalink’s integrated RPM revolution
Vivalink’s Mariel Fabro talks about how integrated remote patient monitoring (RPM) is reshaping decentralized clinical trials.
-
AI in MedTech: Risks, wins, and the road ahead
AI adoption in MedTech lags, but Propel’s Chuck Serrin notes how collaboration and data are unlocking new potential.
-
From risk to readiness: Navigating IRT inspections in clinical trials
As regulators intensify IRT oversight, IQVIA’s Justine Koor outlines how sponsors can prepare and adapt in today’s complex trial landscape.
-
AI in MedTech: Transforming complaint monitoring
IQVIA’s Mike King on how AI enhances complaint handling, product design, and patient safety.
-
The future of AI in healthcare: Why data quality matters
Dr. Mitesh Rao of OMNY Health explains why high-quality, representative data is the key to AI’s success in healthcare.
-
Inside Immunai’s grand collaboration: Mapping the future of immunology
Immunai CEO Noam Solomon discusses the Grand Collaboration Initiative and the future of immune profiling.
-
AI in Pharma: Why regulatory rigor is a catalyst, not a constraint
Ostro CEO Chase Feiger explains how embracing regulation can accelerate AI innovation in life sciences.
-
Balancing the hype and usefulness of AI healthcare
Markus Rothmaier, Head of R&D at Polaroid Therapeutics, talks about how to look beyond the hype to explore more use cases of AI.
Latest posts
-
CTMC maps out plans to democratize cell therapy
CTMC’s Amy Hay details a partnership model to share knowledge and expand cell therapy access worldwide, starting with Brazil.
-
FoRx secures $50 million to advance PARG inhibitor
Swiss biotech raises Series A financing to advance PARG inhibitor FORX-428, with initial clinical data expected in 2026.
-
Milestone Pharma wins FDA nod for self-administered nasal spray for PSVT
The at-home treatment is designed to manage acute symptomatic episodes outside of emergency healthcare settings.